News

April 16, 2023

Researchers Report Clinical Proof-of-Concept Data for Vivace Therapeutics’ VT3989, a First for a Cancer Drug Targeting the Hippo Pathway, in Oral Presentation at AACR 2023

Research and Publications

Publications and Presentations

March 7, 2013

The Hippo Pathway and Human Cancer

Publications and Presentations

November 5, 2015

Hippo Pathway in Organ Size Control, Tissue Homeostasis, and Cancer

News

June 28, 2017

Vivace Therapeutics Comes out of Stealth with $40 Million to Turn Novel Biology into First-in-Class Cancer Therapeutics